AR061352A1 - El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio iv - Google Patents
El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio ivInfo
- Publication number
- AR061352A1 AR061352A1 ARP070102577A ARP070102577A AR061352A1 AR 061352 A1 AR061352 A1 AR 061352A1 AR P070102577 A ARP070102577 A AR P070102577A AR P070102577 A ARP070102577 A AR P070102577A AR 061352 A1 AR061352 A1 AR 061352A1
- Authority
- AR
- Argentina
- Prior art keywords
- alfa
- treatment
- melanoma
- timosina
- malignom
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000007501 Thymosin Human genes 0.000 abstract 1
- 108010046075 Thymosin Proteins 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/32—Thymopoietins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/424,475 US20070292392A1 (en) | 2006-06-15 | 2006-06-15 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
| US11/734,592 US8017129B2 (en) | 2006-06-15 | 2007-04-12 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061352A1 true AR061352A1 (es) | 2008-08-20 |
Family
ID=38323947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102577A AR061352A1 (es) | 2006-06-15 | 2007-06-13 | El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio iv |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8017129B2 (https=) |
| EP (1) | EP2032153A1 (https=) |
| JP (1) | JP2009539916A (https=) |
| KR (1) | KR20090020646A (https=) |
| AR (1) | AR061352A1 (https=) |
| AU (1) | AU2007260145A1 (https=) |
| CA (1) | CA2652516A1 (https=) |
| HR (1) | HRP20090010A2 (https=) |
| IL (1) | IL195955A0 (https=) |
| MX (1) | MX2008015145A (https=) |
| NO (1) | NO20090238L (https=) |
| RU (1) | RU2009101026A (https=) |
| TW (1) | TW200808327A (https=) |
| WO (1) | WO2007144218A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7260764B2 (en) * | 2002-11-26 | 2007-08-21 | Qualcomm Incorporated | Multi-channel transmission and reception with block coding in a communication system |
| US20080300166A1 (en) * | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
| US20100317583A1 (en) * | 2007-12-14 | 2010-12-16 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) |
| ES2356865T3 (es) * | 2008-10-16 | 2011-04-13 | Orion Tech Anstalt | Tratamiento de residuos líquidos que contienen metales pesados. |
| CA2976062C (en) | 2015-02-09 | 2025-05-13 | Sciclone Pharmaceuticals International (Sg) Pte. Ltd. | THYMOSINE ALPHA 1 INTENDED FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS |
| US9861833B1 (en) * | 2017-03-30 | 2018-01-09 | Norman H. Anderson | Methods of treating melanoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888980A (en) * | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5728707A (en) | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
| US6462017B1 (en) * | 2000-05-01 | 2002-10-08 | Sciclone Pharmaceuticals, Inc. | Method of reducing side effects of chemotherapy in cancer patients |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| UA80957C2 (en) | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| UA78726C2 (en) | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| US7101598B2 (en) | 2002-05-22 | 2006-09-05 | Om Nova Solutions Inc. | Self adhering membrane for roofing applications |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| US20080300166A1 (en) | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
-
2007
- 2007-04-12 US US11/734,592 patent/US8017129B2/en active Active
- 2007-04-17 CA CA002652516A patent/CA2652516A1/en not_active Abandoned
- 2007-04-17 MX MX2008015145A patent/MX2008015145A/es not_active Application Discontinuation
- 2007-04-17 KR KR1020087031799A patent/KR20090020646A/ko not_active Withdrawn
- 2007-04-17 WO PCT/EP2007/053712 patent/WO2007144218A1/en not_active Ceased
- 2007-04-17 JP JP2009514721A patent/JP2009539916A/ja not_active Withdrawn
- 2007-04-17 AU AU2007260145A patent/AU2007260145A1/en not_active Abandoned
- 2007-04-17 HR HR20090010A patent/HRP20090010A2/xx not_active Application Discontinuation
- 2007-04-17 RU RU2009101026/15A patent/RU2009101026A/ru not_active Application Discontinuation
- 2007-04-17 EP EP07728177A patent/EP2032153A1/en not_active Withdrawn
- 2007-04-23 TW TW096114301A patent/TW200808327A/zh unknown
- 2007-06-13 AR ARP070102577A patent/AR061352A1/es unknown
-
2008
- 2008-12-15 IL IL195955A patent/IL195955A0/en unknown
-
2009
- 2009-01-14 NO NO20090238A patent/NO20090238L/no not_active Application Discontinuation
- 2009-03-31 US US12/415,589 patent/US8029799B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2032153A1 (en) | 2009-03-11 |
| US20070292393A1 (en) | 2007-12-20 |
| JP2009539916A (ja) | 2009-11-19 |
| US8017129B2 (en) | 2011-09-13 |
| KR20090020646A (ko) | 2009-02-26 |
| NO20090238L (no) | 2009-03-10 |
| IL195955A0 (en) | 2009-09-01 |
| AU2007260145A1 (en) | 2007-12-21 |
| RU2009101026A (ru) | 2010-07-20 |
| HRP20090010A2 (en) | 2009-02-28 |
| CA2652516A1 (en) | 2007-12-21 |
| WO2007144218A1 (en) | 2007-12-21 |
| TW200808327A (en) | 2008-02-16 |
| US20090186000A1 (en) | 2009-07-23 |
| MX2008015145A (es) | 2008-12-15 |
| US8029799B2 (en) | 2011-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA105210C2 (ru) | Противораковая вакцина и ее применение | |
| PL1986669T3 (pl) | Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia | |
| UY27720A1 (es) | Aroilpiridinonas monocíclicas, | |
| CL2008001993A1 (es) | Uso de bacterias probioticas lactobacillus y bifidobacterium en la preparacion de una composicion para normalizar la concentracion de glucosa plasmatica, aumentar la respuesta a insulina y prevenir la diabetes gestacional. | |
| AR061352A1 (es) | El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio iv | |
| PA8534601A1 (es) | Activadores de glucocinasa del tipo isoindolin-1-ona | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| CL2009002206A1 (es) | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. | |
| BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
| CL2011000979A1 (es) | Compuestos derivados ftalazina 1,4-disustituida; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| CL2008003546A1 (es) | Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii. | |
| CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
| ECSP099828A (es) | Uso de ranolazina para peptido natriuretico tipo-cerebral elevado | |
| PL369754A1 (en) | Immunocytokine-containing lyophilized preparation | |
| UY31269A1 (es) | Dispositivo y uso para conservar y poner a disposicion obleas de medicamento | |
| GT200500266A (es) | Nuevos derivados de pirimidina y su uso | |
| PA8824601A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia | |
| CL2008001322A1 (es) | Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| ES2325291A1 (es) | "uso de un extracto de silybum marianum" | |
| GEP20094854B (en) | Compounds for treating diseases of impaired gastric motility | |
| DE602005008607D1 (de) | Im mund zerfallende pharmazeutische zusammensetzung mit risperidon | |
| AR029557A1 (es) | Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |